Multi-Dimensional MRI Spatial Heterogeneity Analysis for Predicting Key Genes and Prognosi
1. To retrospectively explore the feasibility of multi-dimensional heterogeneity imaging features of MRI in predicting the status of key gene mutations in high-grade gliomas; 2. To prospectively explore the correlation between multi-dimensional heterogeneous MRI image features and prognosis of high-grade glioma patient
| Condition(s) | High-grade Glioma |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | 1. To retrospectively explore the feasibility of multi-dimensional heterogeneity imaging features of MRI in predicting the status of key gene mutations in high-grade gliomas; 2. To prospectively explore the correlation between multi-dimensional heterogeneous MRI image features and prognosis of high-grade glioma patients. |
| Who can participate | Inclusion Criteria: Retrospective Study: 1. Participants aged 18 to 70 years, of any gender. 2. Confirmed postoperative pathology of adult diffuse glioma (WHO Grade III-IV). 3. Standard MR contrast-enhanced imaging performed within 10 days before surgery. 4. No history of prior radiotherapy or chemotherapy before surgery. 5. Absence of concurrent significant comorbidities or other tumors. 6. Presence of molecular testing results (including IDH, MGMT, 1p19q, TERT, CDKN2A/B, BRAF). 7. Availability of comprehensive clinical and follow-up data. Prospective Study: 1. Participants aged 18 to 70 years, of any gender. 2. Clinically suspected to have high-grade gliomas preoperatively, with final pathology confirming high-grade gliomas. 3. Stable vital signs and capable of cooperating for a 40-minut |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Lead sponsor | RenJi Hospital |
| Locations | Shanghai, Select A State Or Province, China; Shanghai, Shanghai Municipality, China |
| Start date | 2023-09-01 |
| NCT ID | NCT06002711 |
| Official listing | https://clinicaltrials.gov/study/NCT06002711 |